Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec;12(12):818-34.
doi: 10.1038/nrc3410.

Medulloblastomics: the end of the beginning

Paul A Northcott  1 , David T W Jones, Marcel Kool, Giles W Robinson, Richard J Gilbertson, Yoon-Jae Cho, Scott L Pomeroy, Andrey Korshunov, Peter Lichter, Michael D Taylor, Stefan M Pfister
Affiliations
Review

Medulloblastomics: the end of the beginning

Paul A Northcott et al. Nat Rev Cancer. 2012 Dec.

Abstract

The division of medulloblastoma into different subgroups by microarray expression profiling has dramatically changed our perspective of this malignant childhood brain tumour. Now, the availability of next-generation sequencing and complementary high-density genomic technologies has unmasked novel driver mutations in each medulloblastoma subgroup. The implications of these findings for the management of patients are readily apparent, pinpointing previously unappreciated diagnostic and therapeutic targets. In this Review, we summarize the 'explosion' of data emerging from the application of modern genomics to medulloblastoma, and in particular the recurrent targets of mutation in medulloblastoma subgroups. These data are currently making their way into clinical trials as we seek to integrate conventional and molecularly targeted therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Meta-analysis of medulloblastoma next-generation sequencing studies
(a) Pie chart showing the molecular subgroup distribution within the combined discovery cohort of the three medulloblastoma sequencing studies (n=189)-. (b) Venn diagram showing the number of mutated genes identified in the three next-generation sequencing studies of medulloblastoma (discovery cohorts, n=189) detailed in the text and the degree of overlap between them. Fifteen genes were commonly mutated in all three studies. (c) Frequency (%) and distribution of top candidate genes subject to recurrent non-synomonous mutation (SNV/indel) in medulloblastoma subgroups. Frequency is expressed as the percentage of affected cases within each subgroup and the denominator was dependent on the total number of cases screened for each individual gene (since not all genes were included in the targeted replication cohorts). Genes highlighted in bold were found to be mutated in each of the three sequencing studies. (d) Oncoprints showing the frequency and sample distribution of the most prevalent somatic mutations (SNVs/indels) and focal SCNAs within the medulloblastoma subgroups as determined in the four genomic studies described in the text-, .
Figure 2
Figure 2. Novel mutations and genomic targets in medulloblastoma subgroups
Schematic representations of the most frequently targeted, novel candidate genes in medulloblastoma. Mutation positions are based on the three next-generation sequencing studies described in the text-. Genes are depicted within the subgroup for which they show the greatest enrichment. In Group 3, the zoom box adjacent to MYC depicts the general structure of the recurrent PVT1-MYC fusion genes reported by Northcott et al. In Group 4, the zoom box adjacent to SNCAIP illustrates the general structure of the SNCAIP tandem duplications described by Northcott et al. Abbreviations: DEAD, DEAD domain; LIM, LIM domain; ANK, ankyrin repeat; HLH, helix-loop-helix domain; NIF, NLI interacting factor-like phosphatase; TPR, tetratricopeptide repeat; JmjC, Jumonji C domain; InDel, insertion/deletion.
Figure 3
Figure 3. Convergent deregulation of the histone code in medulloblastoma
Cartoon summarizing a selection of genes recurrently mutated and/or undergoing SCNA in medulloblastoma that are functionally associated with chromatin regulation. Both inactive heterochromatin and active euchromatin and the typical histone marks associated with these chromatin states are illustrated.
Figure 4
Figure 4. Correlation of cytogenetic alterations and somatic mutations within Group 3 and Group 4 medulloblastoma
Distribution of prevalent broad SCNAs and recurrent mutations (SNVs/indels) in Group 3 and 4 medulloblastomas. The majority of both Group 3 and Group 4 medulloblastomas are devoid of somatic mutations in any of the most recurrently mutated genes within these subgroups.
See this image and copyright information in PMC

Similar articles

  • Dissecting the genomic complexity underlying medulloblastoma.
    Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stütz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber UD, Wang Q, Lasitschka B, Bartholomae CC, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts MJ, Russell RB, Coco S, Tonini GP, Schüller U, Hans V, Graf N, Kim YJ, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, von Deimling A, Witt O, Maass E, Rössler J, Ebinger M, Schuhmann MU, Frühwald MC, Hasselblatt M, Jabado N, Rutkowski S, von Bueren AO, Williamson D, Clifford SC, McCabe MG, Collins VP, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott PA, Taylor MD, Meyerson M, Pomeroy SL, Yaspo ML, Korbel JO, Korshunov A, Eils R, Pfister SM, Lichter P. Jones DT, et al. Nature. 2012 Aug 2;488(7409):100-5. doi: 10.1038/nature11284. Nature. 2012. PMID: 22832583 Free PMC article.
  • Novel mutations target distinct subgroups of medulloblastoma.
    Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, Chalhoub N, Baker SJ, Huether R, Kriwacki R, Curley N, Thiruvenkatam R, Wang J, Wu G, Rusch M, Hong X, Becksfort J, Gupta P, Ma J, Easton J, Vadodaria B, Onar-Thomas A, Lin T, Li S, Pounds S, Paugh S, Zhao D, Kawauchi D, Roussel MF, Finkelstein D, Ellison DW, Lau CC, Bouffet E, Hassall T, Gururangan S, Cohn R, Fulton RS, Fulton LL, Dooling DJ, Ochoa K, Gajjar A, Mardis ER, Wilson RK, Downing JR, Zhang J, Gilbertson RJ. Robinson G, et al. Nature. 2012 Aug 2;488(7409):43-8. doi: 10.1038/nature11213. Nature. 2012. PMID: 22722829 Free PMC article.
  • Medulloblastoma molecular dissection: the way toward targeted therapy.
    Remke M, Ramaswamy V, Taylor MD. Remke M, et al. Curr Opin Oncol. 2013 Nov;25(6):674-81. doi: 10.1097/CCO.0000000000000008. Curr Opin Oncol. 2013. PMID: 24076581 Review.
  • Wnt/β-catenin signaling inhibits the Shh pathway and impairs tumor growth in Shh-dependent medulloblastoma.
    Pöschl J, Bartels M, Ohli J, Bianchi E, Kuteykin-Teplyakov K, Grammel D, Ahlfeld J, Schüller U. Pöschl J, et al. Acta Neuropathol. 2014 Apr;127(4):605-7. doi: 10.1007/s00401-014-1258-2. Epub 2014 Feb 15. Acta Neuropathol. 2014. PMID: 24531885 No abstract available.
  • Medulloblastoma: Molecular Classification-Based Personal Therapeutics.
    Archer TC, Mahoney EL, Pomeroy SL. Archer TC, et al. Neurotherapeutics. 2017 Apr;14(2):265-273. doi: 10.1007/s13311-017-0526-y. Neurotherapeutics. 2017. PMID: 28386677 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS. Challenging issues in pediatric oncology. Nature reviews. Clinical oncology. 2011;8:540–9. - PMC - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012;62:10–29. - PubMed
    1. Gajjar A, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. The lancet oncology. 2006;7:813–20. - PubMed
    1. Rutkowski S, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28:4961–8. - PubMed
    1. Ellison DW, et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23:7951–7. - PubMed

Publication types

MeSH terms